Immix Biopharma (IMMX) on Thursday reported initial clinical data from the first four patients in its ongoing trial of NXC-201 CAR-T cell therapy for relapsed/refractory AL Amyloidosis.
All four patients normalized their disease markers within 30 days of treatment, with two achieving a complete response, while the other two showed minimal residual disease negativity in the bone marrow.
The treatment demonstrated good tolerability, with no neurotoxicity, severe cytokine-release syndrome, febrile neutropenia, treatment-related infections, cardiac toxicity, or deaths, the biopharmaceutical company said.
Immix Biopharma said it intends to proceed with enrollment, expecting interim data in Q2 or Q3 2025 and final topline results by Q2 or Q3 2026.
Shares of Immix Biopharma were up 2.8% in recent Thursday trading.
Price: 2.21, Change: +0.11, Percent Change: +5.33
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。